PCOS Gets a New Name: Why Doctors Hope PMOS Changes Far More Than Terminology

The PCOS new name is now official, and it carries hopes that stretch well beyond a simple relabeling. A condition that affects up to one in eight women worldwide, and ranks among the leading causes of infertility, will now be known as polyendocrine metabolic ovarian syndrome, or PMOS.

The shift didn’t happen overnight. It followed more than a decade of debate among medical experts who had long argued that the old name, polycystic ovarian syndrome (PCOS), failed to capture just how far reaching the disorder really is. The change was formally announced in May in the journal The Lancet, and both doctors and patients are hopeful it will lead to faster diagnoses and, eventually, smarter treatments.

A Whole-Body Condition, Not Just an Ovarian One

At its core, PMOS is a hormone disorder that sets off a cascade of effects throughout a woman’s body. That’s exactly why the word “cysts” never quite fit.

“This is a metabolic syndrome that involves many different systems and requires many different specialists to come together,” said Dr. Mibhali Bhalala, an ob-gyn at Kaiser Permanente in Redwood City.

Women living with PMOS often deal with a cluster of symptoms, including:

• Irregular menstrual cycles
• A tendency toward weight gain
• Male pattern hair growth
• Insulin insensitivity, which raises the risk of diabetes and heart problems

The condition has also been linked to sleep apnea, fatty liver disease, and mental health struggles such as depression and anxiety.

Where the Old Name Went Wrong

The disorder was first identified back in the 1930s, originally called Stein–Leventhal syndrome after the doctors who described it. Later, physicians renamed it PCOS after spotting what appeared to be cysts on the ovaries under a microscope.

The problem? Those weren’t really cysts at all. What doctors were seeing were follicles lining the ovary, each holding an immature egg that couldn’t be released. And even that was only one piece of a much larger puzzle.

Centering everything on cysts created real confusion for patients trying to make sense of a sprawling set of symptoms, and it frequently delayed diagnosis. “Hearing ‘polycystic,’ it’s like, ‘Well, I don’t have cysts,'” said Kate Chenoweth, a Los Angeles publicist and former San Francisco resident.

Years of Feeling Dismissed

Chenoweth’s story illustrates the cost of that confusion. Diagnosed with PMOS last year at age 37, she spent decades being told her symptoms were nothing more than “bad periods.” Her struggles began at age 12, when her periods would stretch on for nine days and arrive twice a month. Each time she asked what was wrong, she was told the same thing: nothing.

“You spend your whole life kind of being gaslit into thinking … it’s something you just have to grit your teeth and bear,” she said.

How PMOS Is Diagnosed Now

The rename comes paired with updated diagnostic guidelines. In the past, doctors needed to find cysts on the ovaries to confirm the condition. That requirement is gone. Instead, physicians now weigh three criteria:

• Irregular menstrual cycles
• Elevated levels of male hormones
• Specific ovarian findings on an ultrasound

Crucially, a patient only needs to meet two of those three to receive a diagnosis. “It’s not a black and white diagnosis,” explained Dr. Sun Kim, a Stanford endocrinologist who specializes in treating the condition.

That flexibility reflects how differently PMOS shows up from one woman to the next. For some, it’s tightly bound to insulin resistance, rising blood sugar, and cardiovascular risk. For others, the main signs are irregular periods or difficulty conceiving. Many experience some blend of all of it.

Lifting a Lingering Stigma

Beyond the medical confusion, the old terminology carried an emotional weight too. Some women felt embarrassed by the idea of having cysts on their ovaries.

“People could be discriminated against or it could be stigmatizing, to feel like you have this ovarian fertility condition,” said Dr. Heather Huddleston, director of UCSF’s PMOS clinic. “So for them, moving it away from ‘cysts’ was important.”

The Future of PMOS Research and Treatment

Perhaps the biggest hope tied to the new name is what it could unlock in research. There’s currently no cure for PMOS, and treatment typically relies on lifestyle changes, hormone replacement, and medications like insulin when needed.

Despite affecting roughly 170 million people worldwide, the condition has historically been understudied. Part of the reason, according to Bhalala, is that it was long pigeonholed as a gynecologic issue, an area that tends to receive less research funding than metabolic syndromes. By reframing PMOS as the wide ranging metabolic condition it truly is, doctors hope to draw more funding and open the door to new clinical trials.

“Maybe there are some medications that have been used for diabetes or weight loss that can ultimately work to balance this metabolic syndrome,” Bhalala said. “I think it will open up ways to research this that is not in women’s health corner.”

Why the Change Matters to Patients

For people like Chenoweth, the new name offers something that goes deeper than science. It’s validation for experiences that were dismissed for years, and a roadmap pointing toward answers.

“That all these things are very much explainable, and also to a certain extent treatable, is really empowering,” she said, “and honestly life-changing in terms of just mindset and not feeling like it’s just this endless abyss of no answers.”

In the end, the PCOS new name represents more than updated terminology. It’s a recognition that millions of women have been living with a complex, body wide condition that medicine is only now beginning to fully understand, and the hope is that better understanding will finally translate into better care.